




Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey

Joana Alves^{1,2} · Emine Alp³ · Despoina Koulenti^{4,5} · Zhongheng Zhang⁶ · Stephan Ehrmann^{7,8} · Stijn Blot^{9,10} · Matteo Bassetti¹¹ · Andrew Conway-Morris¹² · Rosa Reina¹³ · Enrique Teran¹⁴ · Candela Sole-Lleonart^{15,16} · Maria Ruiz-Rodríguez¹⁷ · Jordi Rello^{18,19}  · SANEME-2 Investigators

Received: 20 November 2017 / Accepted: 21 December 2017 / Published online: 9 January 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Abstract

2017 ESCMID practice guidelines reported safety concerns and weak evidence of benefit supporting use of aerosolized antibiotics in mechanically ventilated patients. Our primary goal was to assess current patterns of aerosolized antibiotic prescription in mechanically ventilated patients. A sequential global survey was performed prior to the release of the ESCMID guidelines, from the 1st of February to the 30th of April 2017, using an electronic platform. Responses were analyzed comparing geographical regions. A total of 410 units responded, with 261 (177 from Europe) being eligible for the full survey. 26.8% of units reported not using aerosolized antibiotics. The two major indications amongst prescribing units were ventilator-associated pneumonia and ventilator-associated tracheobronchitis (74.3% and 49.4%, respectively). 63.6% of units indicated prescription solely in response to multi-drug resistant organisms. In comparison with a survey undertaken in 2014, there was a significant reduction in use of aerosolized antibiotics for prophylaxis (50.6% vs 7.7%, $p < 0.05$) and colonization (52.9% vs 25.3%, $p < 0.05$). The large majority of units (91.7%) reported only prescribing in patients with positive pulmonary cultures. Asia appeared to be an outlier, with 53.3% of units reporting empirical use. The most commonly used device was the jet nebulizer. The most commonly prescribed drugs were colistin methanesulfonate (57.6%), colistin base (41.9%) and amikacin (31.4%), although there was considerable heterogeneity across geographical areas. A significant gap exists between ESCMID clinical practice recommendations and the use of aerosolized antibiotics in clinical practice. Our findings indicate an urgent need for high-quality education to bring practice into line with evidence-based guidelines.

Introduction

Multi-drug resistant, Gram-negative bacteria (GNB) have risen to worrisome levels worldwide, resulting in increasingly difficult-to-treat infections. Ventilator-associated pneumonia (VAP), the most common infection amongst mechanically ventilated patients, is frequently caused by resistant GNB [1], which have a significant impact on patient outcomes [2, 3].

The pulmonary parenchymal penetration of intravenous antibiotics such as meropenem, amoxicillin and colistin is

markedly inhibited, with alveolar levels reported to be around half of plasma levels [4–6]. Direct pulmonary delivery by aerosolization has been proposed as a potential solution to this problem.

The use of nebulized antibiotics for the treatment of VAP and ventilator-associated tracheobronchitis (VAT) has been hypothesized to result in improved clinical cure rate and better outcomes. This is suggested to be due to increased drug concentrations in the airways, with a potential reduction in side effects such as nephrotoxicity [7–9].

The use of aerosolized antibiotics is supported in the recent 2016 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) VAP guidelines [10]; however, this recommendation is only supported by expert opinion with low-grade evidence. By contrast, based on a meta-analysis of existing studies [11], a GRADE Assessment was conducted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) [12]. ESCMID do not support the use of nebulization of antibiotics in the eight most frequent

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s10096-017-3175-5>) contains supplementary material, which is available to authorized users.

✉ Jordi Rello
jrello@crips.es

List of SANEME-2 Investigators reported at the end of the manuscript in Appendix 1

scenarios based on PICO (Population-Intervention-Comparison-Outcome) questions due to the absence of evidence of benefit and risk of adverse respiratory effects.

In December 2014, a survey exploring the use of aerosolized antibiotics was undertaken, namely, the International Survey of Antimicrobial Nebulization in Mechanically ventilated patients (SANEME) [13]. We performed a new survey in 2017, the SANEME 2, with the following objectives:

1. Assess indications of nebulized agents in the real world, just prior to the publication of the ESCMID guidelines,
2. Characterize dose and frequency of the most common nebulized drugs and compare their use in VAP and VAT,
3. Assess the differences between geographical areas compared to results from the previous survey,
4. To identify the aerosolization devices and techniques which are in current use.

The hypothesis was that the lack of evidence to support the use of nebulized antibiotics would not prevent routine and widespread use.

Methods

This report describes the practices of prescription of aerosolized antibiotics in mechanically ventilated patients from participating units in 2017. An electronic platform survey was undertaken, based on a prior survey [13, 14] modified using the checklist rules suggested by Pulcini and Leibovici [15], between the 1st of February 2017 to the 30th of April 2017. The survey was developed and administered by CONELEC (Tarragona, Spain). The survey was distributed by invitation from members of the Steering Committee (Appendix 2). Only one professional per unit completed the questionnaire to avoid data duplication, although we did not specify the grade or seniority of respondents. No informed consent or ethical board authorization was required.

Questionnaire

Data were collected on the prescription of nebulized drugs, including the indications for use, the agents administered, dose, and aerosolization devices. Regarding dosing regimens, the questionnaire proposed pre-defined doses of colistin, tobramycin and amikacin for therapy of VAP and VAT. Respondents could record as many indications as they wished. The protocol and questionnaire of this project has been reported elsewhere [16].

Study population

Pediatric and neonatal ICUs were not eligible. Sites with five cases or fewer per month were considered ineligible. The

study was designed to collect information on administration practices in units where nebulized antibiotics were used as “standard” prescription in ventilated adults.

Quality control assessment was performed by two investigators (MRR and JA) to ensure consistency and identify potential mistakes. In brief, reports with multiple missing data were identified (the clinical indications sections were mandatory) or major inconsistencies (such as contradictory responses). Unit responses which failed this assessment were excluded. National coordinators (steering committee) were informed, but individual investigators were not contacted. ICUs which reported no use of nebulized antibiotics were analyzed separately, with a focus on their reasons for avoiding nebulization therapy.

Definitions

VAT was defined as the presence of signs of systemic infection and changes in sputum characteristics without the presence of a new radiographic infiltrate in patients receiving mechanical ventilation for at least 48 h. VAP was defined as the presence of progressive, new radiographic infiltrate, signs of systemic infection, changes in sputum characteristics and detection of the causative agent in patients with mechanical ventilation for at least 48 h [10]. Adjunctive use was defined as nebulized antibiotics administered in addition to standard first-line IV antibiotics. Substitution was defined as nebulized antibiotics administered to patients instead of IV antibiotics.

Statistical analysis

Responses were analyzed by using descriptive statistics, reporting proportions (percentages). Data from 2014 have been extracted from reference [13]. Chi-square test was performed to evaluate a potential association between the geographical location of the participants and the particulars of the prescription of nebulized agents, such as their indications or the criteria for initiation of therapy [17].

Availability of data and materials The datasets supporting the conclusions of this article are available upon request.

Results

Respondents from 410 ICUs completed the survey, and the majority (69.7%) reported more than 10 years of clinical experience. After quality control (Fig. 1), 261 ICUs (177 from Europe), with more than five patients treated with nebulized antibiotics in the previous survey month, were eligible for the study (Fig. 2). The majority of ICUs were medical-surgical ($n = 210$, 80.5%). The remaining ICUs were pulmonary ($n = 27$, 10.3%), trauma ($n = 12$, 4.6%), neurosurgical ($n = 8$, 3.1%) and cardiac surgery ($n = 4$, 1.5%).




Fig. 1 Flow chart of ICU surveys

Aerosolized antibiotics were not prescribed in 110 (26.8%) ICUs. The main reasons for not using nebulized antibiotics were lack of appropriate material/resources (43.9%), lack of personal experience in their administration (35.1%), lack of local recommendation (15.8%), weak evidence to support indications (17.5%), and lack of clinical guidelines (12.3%). Even amongst prescribing units, only 25.7% have a specific protocol directing the use of aerosolized antibiotics and the majority (85.1%) believed in the necessity of further randomized control trials to support their use.

Aerosolization devices

Distribution of devices was heterogeneous, and 34 (13%) respondents were not aware of the brand or type of nebulizer used in their ICU. Amongst respondents ($n = 227$), jet nebulizer was the most commonly used (50.4%, $n = 114$), followed by ultrasonic nebulizer (30.7%, $n = 70$), and vibrating-mesh (13.8%, $n = 31$). The remaining 5.1% reported to use “other nebulizers”. The majority of nebulizers ($n = 167$ respondents) were integrated in the ventilator circuit (71.9%, $n = 120$). Regarding ventilator circuit filter change ($n = 216$ respondents), 38.4% ($n = 83$) of units changed the nebulizer filters every day, 25.3% ($n = 55$) twice a week and 18.5% ($n = 40$) once a week. Only 18.1% ($n = 39$) changed filter after every nebulization, as recommended by the manufacturers and guidelines. Ventilator settings when prescribing aerosolized antibiotics are detailed in Table 1.

Antimicrobial prescription

The most common indications (Table 2) for nebulized therapy in respondents were VAP (74.3%, $n = 194$) and VAT (49.4%, $n = 129$), although 166 of 261 (63.6%) only treated in the presence of multi-drug resistant organisms (MDRO). In Asia, after VAP, colonization with MDRO was the second most common indication. Interestingly, the use of aerosolized antibiotics for the prevention of infections was almost exclusively restricted to Asia (29.5%, p value <0.05). In comparison to the 2014 survey (Table 3), respondents were more likely to use nebulized antibiotics for the treatment of VAP. In contrast, a significant reduction (p value <0.05) of use for prophylaxis (50.6% to 7.7%) and treatment of colonization (52.9% to 25.3%) was also reported.

Table 4 displays the use of aerosolized antibiotics for treatment ($N = 230$). Directed therapy with positive pulmonary specimen cultures was the most prevalent indication (91.7%, $n = 211$). However, respondents from Asia used empirical nebulized antibiotics more frequently than the other geographical regions. Empirical therapy was based on an increase of secretions, fever and leucocytosis, and a decrease in PaO₂/FiO₂ ratio or infiltrates on chest radiograph. Compared to 2014 (Table 5), guidance of prescription did not have any differences.

Of note, amongst the 129 units which reported using nebulized antibiotics for VAT therapy, 51.2% ($n = 66$) used nebulized antibiotics as adjunctive therapy only when MDRO were present, 26.4% ($n = 34$) used as adjunctive therapy without considering MDRO and only 17.1% ($n = 22$) used as




Fig. 2 Map of eligible ICUs (map made on GunnMap)

substitution therapy (seven non-respondents). Amongst the 132 respondents that did not select VAT as an indication, 56.1% ($n = 74$) never used nebulized antibiotics for VAT and 24.2% ($n = 32$) did not believe VAT should be treated.

Drugs and dosages

The most common prescribed drugs ($n = 236$) were colistin methanesulfonate (CMS) (57.6%, $n = 136$) and colistin base (41.9%, $n = 99$), followed by amikacin (31.4%, $n = 74$) and tobramycin (25.4%, $n = 60$). Use of other drugs was sporadic

(see Table 6). Interestingly, there was considerable geographic differences in the use of specific drugs: CMS was the most frequent drug used in Europe, whilst colistin base was commonest in Asia and amikacin in the Americas (Table 6).

CMS doses tended to be used at higher median doses (6 and 9 million International Units (MIU), depending on the region) for VAP when compared with VAT (Online Resource Table 7), although there was considerable heterogeneity. For instance, the most commonly prescribed dose of CMS was 2 MIU every 8 h for VAP (28.4%, $n = 55$; total $N = 194$) compared with 1 MIU every 8 h for VAT (26.3%, $n = 30$; total $n = 114$). There was high regional heterogeneity in the most commonly prescribed doses. The most frequent dosage reported for VAP in the Americas (27 units) was 3 MIU 8/8 h ($n = 7$, 25.9%), compared with 2 MIU 8/8 h ($n = 45$, 30.8%) in Europe (146 units) and with 1 MIU 8/8 h ($n = 10$, 47.6%) in Asia (21 units) (Table 7). In contrast, the most commonly prescribed doses for VAP and VAT with amikacin ($n = 111/65$) were 15 mg/kg/12 h (35.1% and 43.1%, respectively) (see Online Resource Table 8). Regarding tobramycin (Online Resource Table 9) the most common doses used for VAP and VAT ($n = 91/61$) were 600 mg/day (44% and 34.4%, respectively).

During the assessment period (1 month), respondents reported the following adverse effects of nebulized antibiotics as common: bronchospasm (23.8%), cough (17.6%), moderate decrease in O₂ saturation (16.9%), moderate increase in peak inspiratory pressure (14.6%), expiratory filter occlusion (8.8%), and nephrotoxicity (6.1%). More rarely encountered side effects (<5.4%) were: severe decrease in O₂ saturation, severe increase in peak inspiratory pressure, arrhythmias, neurotoxicity and anaphylaxis.

Table 1 Ventilator settings when prescribing nebulized antibiotics

Ventilator changes	Total (N = 189) ^a , n (%) ^b
Change characteristics of ventilator breath	48 (25.4)
Increase PEEP	21 (11.1)
Decrease inspiratory flow	20 (10.6)
Use a constant inspiratory flow	48 (25.4)
Increase inspiratory time	38 (20.1)
Insert an end-inspiratory pause	13 (6.9)
Increase tidal volume	21 (11.1)
Stop the active modifier	54 (28.6)
Place a filter on the expiratory limb	56 (29.6)
Use sedation to avoid discoordination with ventilator	26 (13.8)
Use continuous flow or breath actuation	19 (10.1)

PEEP positive end-expiratory pressure

^a Non-responders eliminated

^b Note that responders could indicate as many settings as they wanted, so the sum of results will be different from 100%

Table 2 Indications for the use of nebulized antibiotics

Characteristic	Asia (N = 44), n (%) ^a	Europe (N = 177), n (%) ^a	America (N = 40), n (%) ^a	Total (N = 261), n (%) ^a
VAP treatment	33 (75)	134 (75.7)	27 (67.5)	194 (74.3)
VAT treatment	13 (29.5)	93 (52.5)	23 (57.5)	129 (49.4)
MDRO colonization	15 (34.1)	43 (24.3)	8 (20)	66 (25.3)
Prophylaxis	13 (29.5)*	6 (3.4)	1 (2.5)	20 (7.7)

VAP ventilator-associated pneumonia, VAT ventilator-associated tracheobronchitis, MDRO Multi-drug resistant organisms

^a Note that responders could denote as many indications as they wanted, so the sum of results will be different from 100%

*p value < 0.05, when compared with Europe

Discussion

The present study reports an extended (and heterogeneous) use of adjuvant nebulized antimicrobial agents in ICU patients receiving mechanical ventilation in 2017. Prescription remained restricted to two families of old drugs (colistin and aminoglycosides). Over 90% of units reported use only in response to positive cultures. Units in Asia were distinct in reporting a high rate of empirical use. Three in four ICUs prescribed aerosolized antibiotics for VAP and half for VAT, although 2/3 of respondents limited its use only in the presence of multi-drug resistant organisms. Most ICUs reported the use of devices that are sub-optimal for the generation of appropriate particle size required to reach the distal airways. Moreover, a lack of standardization, with only a minority removing expiratory filters during nebulization raises concerns over both safety and efficacy.

Our survey demonstrates that practitioners continue to frequently use antibiotic nebulization in critically ill patients. It is clear from our survey that the absence of high-quality research in this area is associated with considerable heterogeneity of practice, and suggests significant scope for standardization and improvement of practice. Interestingly, the majority of units used nebulized antimicrobials for VAP and/or VAT therapy, whilst only 25% were using them for MDRO colonization and 8% as prophylaxis, a significant reduction since our last survey (53% and 51%, respectively). These data suggest a shift in the use of these agents to treat confirmed pulmonary

infections relative to 2014, although further follow-up practice surveys will be required to confirm this apparent shift. This change may reflect several factors, including different practices in different geographical regions, the impact of stewardship strategies, emergence of resistance or an absence of high quality evidence and randomized control trials. Interestingly, a recent meta-analysis [18] reported that prophylactic aerosolized antibiotics in mechanically ventilated subjects reduced the occurrence of VAP, without a significant effect on ICU mortality or occurrence of VAP due to MDR pathogens. Considering geographical variations, Asian respondents continue to report the highest use of nebulized antibiotics for both MDRO colonization and prophylaxis, although our survey could not ascertain reasons for this variation in practice.

Regarding VAP and VAT, there was no significant change between 2014 and 2017. As suggested by a well-designed meta-analyses [11] and the 2017 ESCMID Guidelines [12], further high quality research is required. Given the recent nature of the ESCMID guidance, which was published after this survey was conducted, it will be interesting to see if practice changes again in the near future. The clinical challenges due to the increase in extremely- or pan-resistant Gram-negative organisms, create situations reminiscent of the pre-antibiotic era. Our findings confirm that clinicians tend to use aerosolized antibiotics with “old drugs” as ‘salvage therapy’ in patients with multi-resistant organisms in the face of limited therapeutic options, despite the weak evidence supporting efficacy and

Table 3 Comparison between 2014 survey and 2017 on indications for the use of nebulized antibiotics

Characteristic	2014 Total (N = 87), n (%) ^a	2017 Total (N = 261), n (%) ^a	p value
VAP treatment	58 (66.7)	194 (74.3)	0.166
VAT treatment	56 (64.4)	129 (49.4)	0.016
MDRO colonization	46 (52.9)	66 (25.3)	<0.001
Prophylaxis	44 (50.6)	20 (7.7)	<0.001

VAP ventilator-associated pneumonia, VAT ventilator-associated tracheobronchitis, MDRO Multi-drug resistant organisms

^a Note that responders could denote as many indications as they wanted, so the sum of results will be different from 100%

Table 4 Guided prescription of nebulized antibiotics

Characteristic	Asia (N = 30) ^a <i>n</i> (%) ^b	Europe (N = 160) ^a <i>n</i> (%) ^b	America (N = 40) ^a <i>n</i> (%) ^b	Total (N = 230) ^a <i>n</i> (%) ^b
Directed	19 (63.3)*	155 (96.9)	37 (92.5)	211 (91.7)
Empirically	16 (53.3)*	25 (15.6)	4 (10)	45 (19.6)

^a Non-responders eliminated^b Note that responders could denote as many indications as they wanted, so the sum of results will be different from 100%**p* value < 0.05, when compared with Europe

personal reports of significant respiratory and systemic adverse events. Recent trials with aerosolized fosfomycin or amikacin [19, 20] failed to demonstrate efficacy in severe pneumonia. Novel systemic therapies in clinical development or recently approved, such as ceftolozane-tazobactam, ceftazidime-avibactam, cefiderocol, or meropenem-vaborbactam, amongst others are alternative strategies which should hopefully improve the fight against MDR organisms.

Mechanically ventilated patients treated with nebulized antibiotics could be associated with shorter clinical resolution, using either adjunctive or substitution strategies, although it was supported by weak evidence with randomized clinical trials differing from observational studies. Moreover, this effect did not appear to translate into an improvement in mortality or mechanical ventilation duration [11]. Although adverse events were rarely reported in observational studies, respiratory and other adverse events were common in randomized trials. However, there is also the potential to reduce side effects, with a substitution strategy reported to significantly reduce nephrotoxicity (risk difference − 0.33 (95%CI − 0.54 to − 0.12)) when compared with systemic administration [11]. In terms of safety, a randomized, single-blind study [21] confirmed lower nephrotoxicity of aerosolized colistin versus systemic. Currently, there is no known optimum dose and considerable variability amongst the different reports [22–25], although the most commonly used doses are consistent with this survey [23, 25, 26].

The results from our survey reflect the uncertainty amongst clinicians and researchers regarding VAT, with 24% of respondents indicating that VAT should not be treated. This is an area which will need careful consideration in future randomized trials, as will uncertainty about the diagnostic criteria for VAP [10]. Although a wide number of nebulized antimicrobials were described in this study, only colistin and aminoglycosides were

commonly used. There is lack of published pharmacokinetic, clinical outcome, or drug administration data supporting the use of many of these drugs via the inhaled route. From all the existing research [22–24, 27], colistin is the best-understood drug, and consequently the most frequently used in this survey.

To maximize therapeutic efficacy, aerosolization of antimicrobials in ventilated patients requires specific technical requirements [26]. When these requirements are not followed, there are risks of either adverse events or therapeutic failure in mechanically ventilated patients with pneumonia. Optimization of ventilator settings is required to decrease inspiratory flow turbulences and increase nebulization efficiency [27]. Table 1 reports ventilator settings and the findings suggest that educational measures are required to optimize administration. If adequate coordination between the patient and the ventilator is not achieved, implementing sedation with short acting sedative agents are required. A systematic review [28] reported variable aerosol delivery during mechanical ventilation, depending on the device used. For optimal nebulized drug delivery, vibrating-mesh type devices are the most efficient [24, 27], although these devices were used by only 14% of prescribers. Jet nebulizers were used by over half of prescribers, although these deliver less than 15% of the dose to the lung. Only 18% (*n* = 39) of units change filters after every nebulization, as recommended by the manufacturers and guidelines. Lack of removal has been associated with obstruction, increase in respiratory pressure and, if unrecognized, cardiac arrest [27]. These data highlight the need of further educational programmes to improve patient safety, and enhance the effective delivery of these drugs. It is possible that this lack of standardized, safe procedures is related to the high rate of adverse effects reported in this survey.

This survey has several limitations. First, we cannot be certain that all respondents answered questions in the same way.

Table 5 Comparison between 2014 survey and 2017 guided prescription of nebulized antibiotics

Characteristic	2014 Total (N = 76) ^a , <i>n</i> (%) ^b	2017 Total (N = 230) ^a , <i>n</i> (%) ^b	<i>p</i> value Total (N = 230), <i>n</i> (%)
Directed	69 (90.8)	211 (91.7)	0.797
Empirically	15 (19.7)	45 (19.6)	0.974

^a Non-responders eliminated^b Note that responders could denote as many indications as they wanted, so the sum of results will be different from 100%

Table 6 Types of antibiotics nebulized and reported frequency of use by geographic location

Antibiotic type	Asia (N = 29) ^a , n (%) ^b	Europe (N = 168) ^a , n (%) ^b	America (N = 39) ^a , n (%) ^b	Total (N = 236) ^a , n (%) ^b
CMS	8 (27.6)*	110 (65.5)	18 (46.2)*	136 (57.6)
Colistin base	11 (37.9)	67 (39.9)	21 (53.8)	99 (41.9)
Amikacin	6 (20.7)	44 (26.2)	24 (61.5)*	74 (31.4)
Tobramycin	8 (27.6)	37 (22)	15 (38.5)*	60 (25.4)
Gentamicin	7 (24.1)*	17 (10.1)	6 (15.4)	30 (12.7)
Other	10 (34.5)	27 (16.1)	18 (46.2)	55 (23.3)

CMS colistimethate sodium

^a Non-responders eliminated^b Note that responders could denote as many antibiotics as they wanted, so the sum of results will be different from 100%

*p value < 0.05, when compared with Europe

For instance, although we defined VAP and VAT we cannot be certain that respondents used those criteria when answering the questions. Second, data was not always complete from every unit and we cannot exclude this being the result of systematic bias. This questionnaire was only completed by one health-care professional in each intensive care unit, and thus it was not able to evaluate possible intra-unit variation. Although we recruited a relatively large number of units, we did not achieve universal coverage and there is likely to be a degree of responder bias. We also urge caution in reading too much into variations between geographical regions, as these may reflect different sampling populations rather than genuine differences in practice. We also did not recruit from units in Africa and so cannot comment on practice in this continent. Finally, through our efforts to expand the scope of this survey, the comparison with previous iteration must again be treated with caution as the surveyed units were not identical and variation may result from this rather than genuine change in practice over time. This survey has a number of strengths, including its worldwide coverage of intensive care units from low, middle and high-income countries. We were able to recruit a reasonably large number of units, and through careful data quality control we maximized the quality of the data.

In summary, our findings confirm that nebulized antimicrobial agents in mechanically ventilated patient's remains a common clinical practice, particularly for MDRO in VAP (and VAT). Use for colonization and prevention is reported to be less common in most of the world and this is likely to reflect a change in clinical practice over the past few years. Although dosage of colistin used for VAP is double of that used for VAT, marked heterogeneity between geographical areas in terms of choice of antimicrobial agents and dosage regimens was noted. Of additional concern is the lack of standardization of nebulization devices and their safe integration into ventilator circuits. Interestingly, our study emphasizes the gap that exists between clinical practice and the evidence base underpinning it. The

publication of well-designed meta-analysis [11] and guidelines, such as the 2017 ESCMID consensus statement and evidence-based guidelines [12, 27] are welcome but are limited by the current evidence gaps. Our findings suggest that a combination of improved education in the safe use of nebulized therapies and conducting high-quality randomized trials is an urgent need in an era of shortage of antimicrobials for MDRO.

Funding This work was supported in part by a research grant (CB06/06/36) from PCI Pneumonia, CIBERES, Instituto de Salud Carlos III, Madrid, Spain.

Compliance with ethical standards

Guarantor statement and author contribution The first author (JA) undertook the literature search, data analysis, first draft manuscript preparation and is the guarantor for this article. CSL, MRR and JR were responsible for the study design. MRR and JA performed quality assessment. A steering committee (Appendix 2) approved the protocol, provided advice and was responsible for dissemination of the survey. All authors contributed scientifically in subsequent drafts and have approved the final version of the manuscript.

Conflict of interest JR has received research grants and consulting fees from Bayer and Genentech. ZZ has received grants from Zhejiang provincial natural science foundation of China (LGF18H150005). ACM is supported by a Wellcome Trust Clinical Research Career Development Fellowship (WT 2055214/Z/16/Z). MB has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, AstraZeneca, Bayer, Basilea, Cidara, Gilead, Menarini, MSD, Pfizer, The Medicine Company, Paratek, Tetraphase and Vifor. SE has received research grants and research support: Aerogen Ltd., Fisher and Paykel Healthcare, Hamiton Medical; and consulting, honoraria or lecture fees from Aerogen, La diffusion technique française, and Baxter. SB has received fees for advisory board activity from the Bayer advisory board on nebulized amikacin. The remaining authors did not disclose conflicts of interest.

Ethical approval Because this analysis was based on a clinical practice survey, institutional review board approval was not required.

Informed consent As this study does not have individual specific data of patients, informed consent was not applicable.

Appendix 1 - SANEME 2 Study Investigators (Collaborators)

Achilles Rohlfs Barbosa, Adisney Figueroa Olivares, Adriana Ramirez, Akando Benoît, Alberto Noto, Alex Puxty, Aline Yehia, Alistair Roy, Alper Yosunkaya, Ana María Mazzola, Anatilde Diaz, Andrea Pasquale Cossu, Andrew Conway Morris, Andrew Shorr, Angela Hernandez, Anisogloy Sousana, Anoop Nambiar, Anthopoulos Georgios, Antonino Giarratano, Antypa Elli, Apostolos Komnos, Aristeidis Vakalos, Arvaniti Kostoula, Aslıhan Ulu, Attila Hegedus, Avsar Zerman, Ayhan Akbulut, Ayşe Sesin Kocagöz, Aytac Cetinkaya, Bart Vandeveire, Bekos Vasileios, Bilge Cetin, Birgul Yelken, Bo Yu, Boisrame-Helms, Bryan Yates, Burcu Acar Çinleti, Burcu Uysal, Caibao Hu, Carl Gysbrechts, Carlo Olivieri, Carlo Tascini, Carlos Fernando Ordoñez Troya, Carlos Ramirez Paredes, Ceri Battle, Charikleia Nikolaou, Charles Feldman, Chen Kun, Christina Kydona, Christophe Cracco, Christopher Bassford, Chrysostomos Katsenos, Cini Matias, Claudia Carrilho, Colin Cordemans, Cosimo Chelazzi, Csepregi Beáta, Damien Contou, Daniel Duarte, Daniela Olmos Kutscherauer, Danny McAuley, Dario Villalba, Davide Chiumello, Davide D'Antini, Davide Piredda, Despoina Koulenti, Dewi Williams, Diego Maselli, Dikpal Jadhav, Dimitrios K. Matthaiou, Dirk Hoorelbeke, Dirk Rijckaert, Douglas Miesles, Duan Jun, Edy Quizhe, Edison Moraes Rodrigues, Eduardo Luis De Vito, Elizabeth Van der Merwe, Emilio Maseda, Emine Alp, Ennio Fuselli, Enrique Terán, Epaminondas Zakynthinos, Erno Enyedi, Esragul Akinci, Evangelia Douka, Evdokia Tsigou, F. Bavoze, Fabio Silvio Taccone, Faryal Khamis, Fatma Eser, Federico Gonzalez, Felipe Correa, Ferhat Arslan, Fernandez Ruben, Fernando Ortega Berrezueta, Forêt Frédéric, Florent Bavoze, Fraipont Vincent, Francesca Lucchese, Francesco Sbrana, Francesco Zuccaro, Frederico Bruzzi de Carvalho, Ram Mohan, Richards GA, Gabor Uzonyi, Gabriele Racanelli, Marc Gannier, Geng Zhang, Gensheng Zhang, Georgia Lagousakou, Giorgio Tulli, Giovanni Mistràletti, Gokhan Metan, Guillermo Ortiz, Gül Durmuş, Gul Kragoz, Gulden Ersoz, Gulseren elay, Gustavo Armando Carrasco, Gustavo Domeniconi, Gustavo Roncancio, Hector Gustavo Del Pozo Sánchez, Heerman Jan, Henry Caballero, Herbert Spapen, Hitesh Goyal, Hu Yan, Hubert Noemie, Huiqing Ge, Hülya Basar, Hulya Ulusoy, İlhami Çelik, İlhan bahar, Ilker Inanc Balkan, Ioanna Soultati, Ischaki Eleni, Isil Ozkocak Turan, Ismail Hakkı Akbudak, Jale Çelik, Javier Garau, Jesus Humberto Olvera Ibarra, Jhon Byron Leon Grijalva, Jia Song, Jingye pan, Jonathan Bannard-Smith, Jonathan Rhodes, Jonathan Richards, Jordi Rello, Jordi Sole Violan, Jorge Alberto Neira, Jose Carlos Celia, Jose Vergara-Centeno, Juan Domingo Fernández, Juan P. Osorio, Kallirroï Kefala, Kamil Gonderen, Karathanou Antigoni, Karim Lakhal, Karolien Dams, Katia

Aparecida Pessoa Conde, Kedar Takalkar, Killen Briones Claudeth, Kontoudaki Eftychia, Kubilay Demirag, Kursat Gundogan, Lagos Nikolaos, Laurent Argaud, Laxman Jessani, Leandro Ballatore, Leonel Lagunes, Liang Luo, Lidia Dalfino, Lionel Haentjens, Li Yongxin, Loreto Vidaur, Lu Qin, Lucia Serio, Luis Alejandro Leon Guerrero, Luís Felipe, Luis Silva, M. Kartik, Manisha Gupta, Manuel Jose Rivera Chavez, Marcela Susana Gilli, Marcelo Maia, Marcio Borges, Marco Falcone, Marcos I. Restrepo, Maria Hobrok, Maria Petraki, Maria Theodorakopoulou, Maria Virginia Rodriguez Alexieva, Marin Kollef, Marina Oikonomou, Mark Kol, Marlo Palacios Guerrero, Martha Michalia, Martin Deheza, Massimo Girardis, Mauricio Gonzalez, Matteo Bassetti, Maurilio Festa, Mehmet Uyar, Melda Türkoğlu, Mengyan Chen, Metaxia Papanikolaou, Miguel Chung Sang, Mohammed Irfanulla, Moises Loo Intriago, Monica Placencia Orellana, Murat Gündüz, Murat Sayin, Mustafa Kaçmaz, Nagky Eva, Nakos George, Nathalie Layios, Nele Guion, Neeraj Manikath, Nicola Walid, Nikolaas De Neve, Nikolaos Markou, Nikoletta Rovina, Nuray Özgür Abravci, Oguz Karabay, Oktay Demirkiran, Orhan Behret, Paolo Nahuel Rubatto Birri, Orosz János, Papadakis Emmanouil, Papanikolaou Spiros, Paridou Alexandra, Patricia Castellar Galván, Patricia Sánchez, Paul Hayden, Paul Ramiro Cobos Villavicencio, Paula Juarez, Pedro Torres, Peter Anderson, Philippe Berger, Philippe Mateu, Phunsup Wongsurakiat, Pierluigi Brugnaro, Pierre Damas, Pinar Zeyneloglu, Polychronis Malliotakis, Qian Li, Qin Lu, Rafael Franco-Cendejas, Rafael Mañez, Rafael Zaragoza, Rahmet Guner, Rajesh Kumar, Rajiv Dhand, Ramazan Ulu, Raul Ortega, Ravani Ifigenia, Reners Eddy, Renhua Sun, Ricardo Serrano, Richard Pugh, Richard Wunderink, Rolando Ojeda Piedra, Rosa Reina, Rusniev Erik Tapia Rodriguez, Saba saygılı, Sadanandan Prakash, Sakagianni Katerina, Sami Kalin, Sara Benitez Burgos, Sebastien Jochmans, Seda Banu Akinci, Sedef Tavukcu Ozkan, Serpil Ocal, Sfyras Dimitrios, Sheng Ye, Shuguang Zheng, Shekhar Kunal, Stijn Blot, Sulekha Saxena, Sophie Perinel, Stavros Aloizos, Stefania Artioli, Stefano Busani, Stephan Ehrmann, Stephen Bonner, Stephen Wright, Sunil Kumar, Sukran Kose, Therese Starr, Thiago Lisboa, Thierry Hernández-Gilsoul, Tobias Welte, Tony Bruyns, Valentina Ortiz-Milosevic, Varun Kumar Singh, Vasileios Koulouras, Vasileios Zochios, Vasiliki Koutsoukou, Vasiliki Romanou, Vimal Kumar, Virginia Intriago Cedeño, Wagner Nedel, Walter Swinnen, Wan Minmin, Xiaoyun Hu, Xie Bo, Ximena Palomino, Xuqing Ji, Yasemin Cag, Yenny Cardenas, Yosdel Martinez Hernandez, Yuetian Yu, Yusuf Savran, Zahid Ahmed, Zeynep Türe Yüce, Zhang Jun Wei, Zhixian Qian, Zhongheng Zhang, Zhu Zhenhua, Zsolt Molnar.

Appendix 2 - Steering committee


1. Chair of Steering committee: Jordi Rello – jrello@crisps.es
2. Emine Alp - aeminea@hotmail.com
3. Despoina Koulenti - d.koulenti@uq.edu.au
4. Zhongheng Zhang - zh_zhang1984@zju.edu.cn
5. Stephan Ehrmann - stephanehrmann@gmail.com
6. Stijn Blot - Stijn.Blot@ugent.be
7. Matteo Bassetti - mattba@tin.it
8. Andrew Conway-Morris - ac926@cam.ac.uk
9. Manisha Gupta - dreamsmaterialise@gmail.com
10. Rosa Reina - rosireina@gmail.com
11. Marin Kollef - kollefm@wustl.edu
12. Juan P. Osorio - juanosoriol@gmail.com
13. Enrique Terán - eteran@usfq.edu.ec
14. Thiago Lisboa - tlisboa@hcpa.edu.br
15. Leonel Lagunes - leonel.lagunes@gmail.com
16. Zsolt Molnar - z_molnar@hotmail.com
17. Faryal Khamis - khami001@gmail.com
18. Charles Feldman - Charles.feldman@wits.ac.za
19. Tobias Welte - Welte.Tobias@mh-hannover.de

References

1. Barbier F, Andremont A, Wolff M, Bouadma L (2013) Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. *Curr Opin Pulm Med* 19(3):216–228. <https://doi.org/10.1097/MCP.0b013e32835f27be>
2. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, Cohen MM, Fraser VJ (2003) Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. *Crit Care Med* 31(5):1312–1317. <https://doi.org/10.1097/01.CCM.0000063087.93157.06>
3. Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. *Am J Respir Crit Care Med* 165(7):867–903. <https://doi.org/10.1164/ajrccm.165.7.2105078>
4. Valcke Y, Pauwels R, Van der Straeten M (1990) Pharmacokinetics of antibiotics in the lungs. *Eur Respir J* 3(6):715–722
5. Rottboll LA, Friis C (2016) Penetration of antimicrobials to pulmonary epithelial lining fluid and muscle and impact of drug physicochemical properties determined by microdialysis. *J Pharmacol Toxicol Methods* 78:58–65. <https://doi.org/10.1016/j.vascn.2015.11.007>
6. Kiem S, Schentag JJ (2008) Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. *Antimicrob Agents Chemother* 52(1):24–36. <https://doi.org/10.1128/AAC.00133-06>
7. Valachis A, Samonis G, Kofteridis DP (2015) The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. *Crit Care Med* 43(3):527–533. <https://doi.org/10.1097/CCM.0000000000000771>
8. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, Varela M, Tempone AK, O'Riordan T, Daroowalla F, Richman P (2008) Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. *Crit Care Med* 36(7):2008–2013. <https://doi.org/10.1097/CCM.0b013e31817c0f9e>
9. Palmer LB, Smaldone GC (2014) Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. *Am J Respir Crit Care Med* 189(10):1225–1233. <https://doi.org/10.1164/rccm.201312-2161OC>
10. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratala J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* 63(5):e61–e111. <https://doi.org/10.1093/cid/ciw353>
11. Sole-Lleonart C, Rouby JJ, Blot S, Poulakou G, Chastre J, Palmer LB, Bassetti M, Luyt CE, Pereira JM, Riera J, Felton T, Dhanani J, Welte T, Garcia-Alamino JM, Roberts JA, Rello J (2017) Nebulization of Antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. *Anesthesiology* 126(5):890–908. <https://doi.org/10.1097/ALN.0000000000001570>
12. Rello J, Sole-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, Luyt CE, Riera J, Palmer LB, Pereira JM, Felton T, Dhanani J, Bassetti M, Welte T, Roberts JA (2017) Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. *Clin Microbiol Infect* 23(9):629–639. <https://doi.org/10.1016/j.cmi.2017.04.011>
13. Sole-Lleonart C, Roberts JA, Chastre J, Poulakou G, Palmer LB, Blot S, Felton T, Bassetti M, Luyt CE, Pereira JM, Riera J, Welte T, Qiu H, Rouby JJ, Rello J, Investigators E (2016) Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. *Clin Microbiol Infect* 22(4):359–364. <https://doi.org/10.1016/j.cmi.2015.12.016>
14. Sole-Lleonart C, Rouby JJ, Chastre J, Poulakou G, Palmer LB, Blot S, Felton T, Bassetti M, Luyt CE, Pereira JM, Riera J, Welte T, Roberts JA, Rello J (2016) Intratracheal administration of antimicrobial agents in mechanically ventilated adults: an international survey on delivery practices and safety. *Respir Care* 61(8):1008–1014. <https://doi.org/10.4187/respcare.04519>
15. Pulcini C, Leibovici L, Office CMIE (2016) CMI guidance for authors of surveys. *Clin Microbiol Infect* 22(11):901–902. <https://doi.org/10.1016/j.cmi.2016.08.015>
16. Rello J, Ruiz-Rodriguez M, Zhang Z (2017) 2017 global survey on nebulization of antimicrobial agents in mechanically ventilated patients—SANEME 2 study protocol. *Journal of Emergency and Critical Care Medicine* 1 (5). <https://doi.org/10.21037/jeccm.2017.04.01>
17. Zhang Z (2016) Univariate description and bivariate statistical inference: the first step delving into data. *Ann Transl Med* 4(5):91. <https://doi.org/10.21037/atm.2016.02.11>
18. Povoa FCC, Cardinal-Fernandez P, Maia IS, Reboredo MM, Pinheiro BV (2017) Effect of antibiotics administered via the respiratory tract in the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. *J Crit Care* 43:240–245. <https://doi.org/10.1016/j.jcrc.2017.09.019>
19. Kollef MH, Ricard JD, Roux D, Francois B, Ischaki E, Rozgonyi Z, Boulain T, Ivanyi Z, Janos G, Garot D, Koura F, Zakynthinos E, Dimopoulos G, Torres A, Danker W, Montgomery AB (2017) A randomized trial of the amikacin Fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia: IASIS trial. *Chest* 151(6):1239–1246. <https://doi.org/10.1016/j.chest.2016.11.026>
20. Bayer (2017) Phase III study program with amikacin inhale in addition to standard of care in intubated and mechanically ventilated patients with gram-negative pneumonia does not meet primary endpoint of superiority. Press Release PRNewswire

21. Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Ben Lakhal S (2016) Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. *Ann Intensive Care* 6(1):26. <https://doi.org/10.1186/s13613-016-0127-7>
22. Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, Golmard JL, Rouby JJ, Nebulized Antibiotics Study G (2012) Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Anesthesiology* 117(6):1335–1347. <https://doi.org/10.1097/ALN.0b013e31827515de>
23. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A (2009) Inhaled colistin as monotherapy for multidrug-resistant gram (–) nosocomial pneumonia: a case series. *Respir Med* 103(5):707–713. <https://doi.org/10.1016/j.rmed.2008.11.018>
24. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME (2008) Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: a prospective study. *Respir Med* 102(3):407–412. <https://doi.org/10.1016/j.rmed.2007.10.011>
25. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V (2010) Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. *J Antimicrob Chemother* 65(12):2645–2649. <https://doi.org/10.1093/jac/dkq360>
26. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME (2010) Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. *Clin Microbiol Infect* 16(8):1230–1236. <https://doi.org/10.1111/j.1469-0691.2009.03040.x>
27. Rello J, Rouby JJ, Sole-Lleonart C, Chastre J, Blot S, Luyt CE, Riera J, Vos MC, Monsel A, Dhanani J, Roberts JA (2017) Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. *Clin Microbiol Infect* 23(9):640–646. <https://doi.org/10.1016/j.cmi.2017.03.018>
28. Dugernier J, Ehrmann S, Sottiaux T, Roeseler J, Wittebole X, Dugernier T, Jamar F, Laterre PF, Reyckler G (2017) Aerosol delivery during invasive mechanical ventilation: a systematic review. *Crit Care* 21(1):264. <https://doi.org/10.1186/s13054-017-1844-5>

Affiliations

Joana Alves^{1,2} · Emine Alp³ · Despoina Koulenti^{4,5} · Zhongheng Zhang⁶ · Stephan Ehrmann^{7,8} · Stijn Blot^{9,10} · Matteo Bassetti¹¹ · Andrew Conway-Morris¹² · Rosa Reina¹³ · Enrique Teran¹⁴ · Candela Sole-Lleonart^{15,16} · Maria Ruiz-Rodríguez¹⁷ · Jordi Rello^{18,19} 

¹ Infectious Diseases Department, Centro Hospitalar São João, Porto, Portugal

² Faculty of Medicine of University of Porto, Porto, Portugal

³ Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey

⁴ BTCCRC, UQCCR, Faculty of Medicine, The University of Queensland, Brisbane, Australia

⁵ 2nd Critical Care Department, Attikon University Hospital, Athens, Greece

⁶ Department of Emergency Medicine, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China

⁷ Médecine Intensive Réanimation, CHRU de Tours and CRICS-TriggerSEP Network, Tours, France

⁸ Centre d'étude des pathologies respiratoires, INSERM U1100, Aérosolthérapie et biomédicaments à visée respiratoire, Faculté de médecine de Tours, Université François Rabelais, Tours, France

⁹ Department of Internal Medicine, Faculty of Medicine & Health Science, Ghent University, Ghent, Belgium

¹⁰ Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia

¹¹ Infectious Diseases Division, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata, Udine, Italy

¹² University Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK

¹³ Terapia Intensiva, Hospital Interzonal de Agudos “General San Martín”, La Plata, Argentina

¹⁴ Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito, Ecuador

¹⁵ Centre Hospitalier Universitaire Vaudoise, Geneva, Switzerland

¹⁶ Universitat Autònoma de Barcelona, Barcelona, Spain

¹⁷ Department of Clinical Research & Innovation in Pneumonia and Sepsis, Vall d'Hebron Institut of Research, Barcelona, Spain

¹⁸ Critical Care Department, Vall d'Hebron Institut of Research, Barcelona, Spain

¹⁹ Centro de Investigación Biomedica en Red (CIBERES), Ps Vall d'Hebron 119, AMI- 14a Planta, 08035 Barcelona, Spain